Aquestive Secures $150M Debt Facility, Refinances Existing Debt, and Reports Strong Q1 Earnings

summarizeSummary

Aquestive Therapeutics secured a new $150 million debt facility, refinancing existing debt and providing crucial capital for future operations, while also reporting strong Q1 2026 financial results with increased revenue and reduced losses.

check_boxKey Events

• $150 Million Debt Facility Secured

  The company entered into a five-year term loan facility of up to $150 million with Oaktree Fund Administration, LLC. An initial $55 million was funded immediately, with additional tranches of $20 million, $25 million, and $50 million available upon FDA approval of Anaphylm, achievement of sales milestones, and mutual consent, respectively.

• Existing Debt Refinanced

  A portion of the initial $55 million from the new facility was used to repay in full the existing $45 million outstanding indebtedness, eliminating near-term principal payments and improving the company's debt structure.

• Strong Q1 2026 Financial Results

  Total revenues increased by 66% to $14.4 million in Q1 2026 from $8.7 million in Q1 2025. Net loss significantly decreased to $8.1 million from $22.9 million in the prior year, and non-GAAP adjusted EBITDA loss improved to $1.7 million from $17.6 million.

• Anaphylm NDA Resubmission on Track

  The company reaffirmed its guidance to resubmit the Anaphylm New Drug Application (NDA) in Q3 2026, following a successful Type A meeting with the FDA to align on study designs.

auto_awesomeAnalysis

Aquestive Therapeutics has secured a critical $150 million debt facility, with $55 million immediately funded, which significantly strengthens its balance sheet and extends its cash runway. This financing is crucial for the company's ability to fund the potential launch of Anaphylm, especially following recent FDA regulatory setbacks. The deal also refinances existing debt, reducing near-term principal payments. Concurrently, the company reported strong first-quarter financial results, with a substantial increase in revenue and a significant reduction in net loss, indicating improved operational performance. Positive updates on Anaphylm's regulatory path and AQST-108's clinical development further bolster investor confidence.